<DOC>
	<DOCNO>NCT01905969</DOCNO>
	<brief_summary>Adjuvant chemotherapy follow curative gastrectomy Stage II/III gastric cancer improve disease free time survival . However , still considerable number patient experience relapse even adjuvant chemotherapy . In attempt select patient really benefit postoperative adjuvant chemotherapy , identify potential biomarkers ( NF-kappaB/JNK ) cell line panel screening follow immunohistochemical validation . In present study , validate significance biomarkers large set clinical sample see chemotherapeutic response determine immediately surgery .</brief_summary>
	<brief_title>Predictive Biomarkers Stage II/III Gastric Cancer Adjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Pathologically confirm gastric cancer . Operated November 2009 . Stage Ib/II ( except T1 , T3N0 ) /III . Received postoperative ( R0 ) adjuvant chemotherapy ( S1 ) . Not receive postoperative ( R0 ) adjuvant chemotherapy ( surgery alone ) . Signed informed consent provide paraffin embed tissue remove specimen . With advanced neoplastic lesion gastric cancer . Paraffin embed tissue available . Unknown S1 treatment condition .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Gastric caner , adjuvant chemotherapy</keyword>
</DOC>